Key TakeawaysSeamless Therapeutics and Eli Lilly collaborate to develop genetic medicines for hearing loss using recombinase technology.The recombinase platform enables precise DNA insertions without relying on endogenous DNA repair pathways.Seamless will design recombinases, and Lilly will advance them through preclinical and clinical stages.The agreement includes potential payments of up to $1.12 billion, excluding royalties on […]
